Sun BioPharma to Begin Dosing Pancreatic Cancer Patients in Clinical Trials (Globe Newswire)

Sun BioPharma to Begin Dosing Pancreatic Cancer Patients in Clinical Trials (Globe Newswire)

UF startup Sun BioPharma, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, provided a business update and reports financial results for the quarter ended March 31, 2018.

The Company’s newest trial, a combination of SBP-101 to be administered with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (PDA), is expected to begin dosing patients by the end of May 2018. Site initiation visits have been completed at 2 of 4 participating cancer centers: the Adelaide Cancer Centre in Adelaide, Australia, and the University of Florida in Gainesville, Florida where SBP-101 was invented. Both centers are actively recruiting subjects for the study. Two additional sites, both in Australia, will be initiated in June of 2018. This study includes a dose-escalation phase with sequential cohorts of patients receiving treatment at each of three SBP-101 dose levels. The dose-escalation phase will be followed by an expansion phase at the optimal dose level of SBP-101. The study has been registered on the clinicaltrials.gov website.

Learn more about Sun BioPharma to Begin Dosing Pancreatic Cancer Patients in Clinical Trials.

X